FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly oncology, and can be used to reduce the number of tumor stem cells (TSC). Method for reducing the number of stem cells of breast cancer involves 72-hour exposure on tumor cells in vitro of DNA-binding ligands – water-insoluble dimeric bis-benzimidazoles. Incubation is carried out with water-insoluble dimeric bisbenzimidazole with 5 methylene links in linker DB (5) or water-insoluble dimeric bisbenzimidazole with 7 methylene links DB (7) in vitro at a temperature of +37 °C for 3 days, after which amount of CD44+CD24-/1ow tumor stem cells is evaluated.
EFFECT: use of the given method reduces amount of OSK, which are more chemo-and radioresistant than the rest mass of tumor cells, which allows to increase chemo- and radiosensitivity of tumor as a whole, which in its turn will promote higher clinical effectiveness.
1 cl, 4 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF REDUCING THE NUMBER OF STEM CELLS OF HUMAN BREAST ADENOCARCINOMA | 2022 |
|
RU2798550C2 |
| METHOD FOR SUPPRESSING THE INDUCING ACTION OF HIGH MOLECULAR WEIGHT HYALURONIC ACID ON BREAST CANCER STEM CELLS | 2021 |
|
RU2774031C1 |
| METHOD OF INHIBITING RADIATION-INDUCED INCREASE IN HUMAN BREAST CANCER STEM CELLS | 2022 |
|
RU2800366C2 |
| METHOD FOR REDUCING CLONOGENIC ACTIVITY OF LACTEAL GLAND CANCER STEM CELLS | 2019 |
|
RU2700695C2 |
| METHOD FOR DETERMINING THE REDUCTION OF RADIATION-INDUCED MIGRATION OF HUMAN BREAST CANCER CELLS OF THE MCF-7 LINE | 2022 |
|
RU2789099C2 |
| METHOD FOR PREDICTION OF RADIOSENSITIVITY OF MALIGNANT GROWTHS OF UPPER RESPIRATORY TRACT | 2020 |
|
RU2735982C2 |
| METHOD OF ASSESSING THE ABILITY OF BREAST CANCER CELLS TO DEDIFFERENTIATE USING THE METHOD OF SPHEROID FORMATION | 2022 |
|
RU2805842C1 |
| METHOD OF INCREASING THE EFFICIENCY OF PROTON THERAPY ON MELANOMA STEM CELLS | 2022 |
|
RU2798733C2 |
| PLASMID FOR REVEALING EPITHELIAL STATE OF HUMAN CELL | 2019 |
|
RU2716054C1 |
| METHOD FOR PREDICTING THE RISK OF POOR TUMOR RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH INVASIVE BREAST CANCER | 2018 |
|
RU2682967C1 |
